Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0677481 (urinary frequency)
 1,126 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

1. Among all tissue examinations, 8.6% were on male urogenital organs, of which 2.9% were for carcinoma of the prostate. Biopsies of the prostate comprised a large percentage of all male urogenital biopsies. Since the specimens examined by various pathological laboratories in Tehran were received from all over the country, comparison of these statistics is significant. 2. Male urogenital tumors comprised 6.7% of male biopsies, of which 2.7% were for tumors of the prostate. 3. Male urogenital cancers comprised 2.3% of biopsies examined, of which only four were prostatic carconomas. Carcinoma of the prostate was the rarest cancer of the male urogenital organs in Iran. 4. We found 933 cases of cancer of male urogenital organs in 31 years. This comprised 6% of all male cancers, of which only 0.33% were carcinoma of the prostate. 5. Bladder carcinomas were the commonest and prostate carcinomas the rarest among males. 6. We found that 97% of prostate tumors were benign and 3% were malignant. Prostatic carcinoma was four times more prevalent among high income patients than among low income patients. 7. Benign tumors were most common in the 40 to 70 age groups, whereas the peak incidence for carcinoma of this organ was 50 to 70 years of age. 8. No particular clinical symptoms were found. Most patients reported pollakiuria, dysuria or urinary retention. 9. The initial growth site of tumors in the few cases that we were able to study was in the cortex region, especially from the posterior lobe. 10. Histological types of tumor found did not differ from other figures reported. We found no sarcomas. 11. No systematic study of asymptomatic nodules of carcinoma of the prostate has been made and we have never found any signs of such solitary nodules. This may be due to the low average age and the rarity of malignancy of the prostate in Iran. 12. The frequency of death in Iran due to carcinoma of the prostate is impossible to state since death certificates, in the majority of cases, specify secondary symptoms of the disease and not the original disease. 13. The incidence of prostatic carcinoma in the provice of Fars was five times greater and in Isfahan four times greater than in the province of Tehran. However, the figures for Tehran were compiled over the last 31 years, whereas the figures for Isfahan and Shiraz are only for the last ten years, and comparison of these three sets of figures may not be accurate. 14. Carcinoma of the prostate is not as common in Iran as it is in Europe and America. It is rather rare in Iran and compares favorably with figures for the Near Eastern and Far Eastern countries. The Middle Eastern countries of Lebanon, Israel and Afghanistan are very similar in incidence to Iran. In other countries in our region, the incidence is 1.8%.
 ...
PMID:Prostatic tumors in Iran. 115 17

Thirty-eight workers from a factory producing nickel-cadmium and other types of batteries came to us for medical evaluation. They included 21 women and 17 men (seniority 2-20 years, age range 31-63 years), and represented a self-selected subset of 700-900 ever-employed and 200+ recently or currently employed workers in the factory. Thirty-four worked on the nickel-cadmium assembly line. Symptoms and signs included: headache in 34; weakness, fatigue and lassitude in 26; dizziness in 16; pruritus and skin eruptions in 37; gingivitis, teeth loss and caries in 34; nasal congestion, nosebleeds and anosmia in 30; cough, phlegm production, wheezing and shortness of breath in 26; "asthma" in 14; bone pain in 18; urinary frequency, beta 2 microglobulinuria and kidney stones in 17; and sterility or multiple abortions (33) in 8 of 21 women. One additional patient had died from an "amyotrophic lateral sclerosis-like syndrome", while CT scans in six workers revealed brain atrophy. One other worker had leukemia, and two had died from cancer (lung and pancreas). Those who had worked for more than 10 years had more symptoms and signs than shorter-term employees, especially neurological illness, bone pain and urinary tract problems, including beta 2 microglobulinuria. Past blood and urinary cadmium levels were in the range of 1.6-8.7 micrograms/dl and 8-306 micrograms/l, respectively. Our findings indicated that: a) health risks for workers were not confined to the nickel-cadmium assembly line or to older workers, b) hazardous exposures still existed and illness appeared in new workers after a clean-up and intervention program, and c) exposures involved increased risks for renal disease and cancers. Finally, there is a need to control exposures and determine health risks in the full cohort of those ever employed, in the workers' children, and in the surrounding environment (air, ground, water) due to the dumping of waste from the plant.
 ...
PMID:Medical findings in nickel-cadmium battery workers. 142 13

Forty patients with carcinoma in situ of the bladder were reviewed. They included 15 patients with primary carcinoma in situ, 8 with secondary carcinoma in situ and 17 with concurrent carcinoma in situ. Twenty-one (66%) of 32 patients with primary or concurrent carcinoma in situ complained of urinary frequency and pain on urination, whereas no patients with secondary carcinoma in situ complained of such symptoms. Nearly all patients with concurrent or secondary carcinoma in situ had gross hematuria, whereas only 7 (47%) of 15 patients with primary carcinoma in situ had gross hematuria. Two patients without any symptoms were diagnosed by incidental positive urinary cytology. Concurrent carcinoma in situ was always associated with multiple papillary tumor. Dominant grade of the papillary tumor was classified as grade 3 in 11 patients and as grade 2 in 6. The simultaneous presence of carcinoma in situ of the urethra was found in 13 (46%) patients and those of the ureter in 17 (74%). Fourteen patients (35%) with carcinoma in situ developed an invasive carcinoma. Of these, 4 (10%) died of cancer. Bacillus calmette-guerin instillation was effective in 13 of 15 patients (87%). These results indicate that carcinoma in situ of the bladder may develop an invasive cancer, may remain in the epithelia, or may be associated with multiple superficial tumor. It should be emphasized that patients with multiple superficial bladder tumor may be associated with carcinoma in situ even if the superficial tumors are of low grade and urine cytology is negative.
 ...
PMID:[The progress pattern of carcinoma in situ of the urinary bladder]. 192 Oct 16

A 45 year old female who received radiotherapy for stage II-B uterine cervical cancer four and half years ago, presented with persistent hematuria due to radiation cystitis. 15 (S)-15-methyl prostaglandin F2-alpha (1 mg in 100 ml of normal saline) was instilled into the bladder daily for two days. The severity of bleeding decreased considerably. However, significant hematuria recurred 19 days later which continued despite bladder irrigation with normal saline. 1 mg of 15 (S) 15-Me PGF2 alpha mixed with hydroxyethyl cellulose gel to a volume of 10 ml was then instilled into the urinary bladder daily for three days and macroscopic hematuria ceased. Urinary frequency and urgency were the side effects which lasted for ten days. There has been no recurrence of macroscopic hematuria during the five months follow-up. In conclusion, 15 (S) 15-Me PGF2-alpha may be administered intravesically to control moderate hematuria due to radiation cystitis.
Indian J Cancer 1989 Jun
PMID:Control of persistent vesical bleeding due to radiation cystitis by intravesical application of 15 (S) 15-methyl prostaglandin F2-alpha. 259 3

In order to examine its clinical efficacy, recombinant human interferon-beta (rIFN-beta) was instilled intravesically into 51 patients with superficial bladder cancer. Ten patients, who received intermittent intravesical instillation at a dose of (3-36) x 10(6) U rIFN-beta on days 1-3 every week, showed no response. Thirty-two patients received intravesical instillation at a dose of (3-36) x 10(6) U every day for 10-20 days. Eight patients showed partial response, indicating an efficacy rate of 25%. Nine patients received divided doses of 18 x 10(6) U twice a day every day for 10-20 days. Six patients showed partial response, indicating an efficacy rate of 67%. This value was significantly higher than that obtained by administering divided doses. The response to intravesical instillation therapy with rIFN-beta varies with treatment protocol. Frequent and longer exposure to rIFN-beta may induce better regression of superficial bladder cancer. Six incidences of side-effects were found in five cases (9.8%): pollakiuria in one, pain on micturition in two, fever in two, and eruption in one case. All of these side-effects were slight and reversible after drug withdrawal. Laboratory tests showed only a few changes with low severity. Thus, rIFN-beta is potentially a new drug for instillation therapy of superficial bladder cancer, in view of the absence of adverse effects.
Cancer Immunol Immunother 1989
PMID:Intravesical treatment of bladder cancer with recombinant human interferon-beta. Intravesical GKT-beta Chemotherapy Research Group. 259 81

Two cases of carcinoma in a diverticulum of the bladder were experienced. The first case was of a 50-year-old male who presented in February, 1981, complaining of asymptomatic microhematuria. The excretory urogram revealed a diverticulum in the left lateral aspect of the bladder which was causing shift of the lower ureter to the median side. The cytology report of voided urine was class III. Diverticulectomy was performed and pathologic findings was a transitional cell carcinoma, grade 1, stage 0. The patient has been free of recurrence for the past 54 months. The second case was of a 67-year-old male with the chief complaint of pollakiuria. Non-papillary tumor in a diverticulum of the bladder was found by cystoscopy and computed tomography. Tumor biopsy and urinary diversion by ileal conduit were performed in the usual manner. The pathologic finding was transitional cell carcinoma of grade 11 malignancy. The patient died of intestinal obstruction on January, 19, 1984, about 15 months after the surgery. The 117 cases of carcinoma in a diverticulum of the bladder we found in the Japanese literature are reviewed briefly.
 ...
PMID:[Primary carcinoma in a diverticulum of the bladder: a report of two cases]. 311 31

Ten patients with advanced bladder cancer were treated with intra-arterial infusion therapy. The patients consisted of nine males and one female between 55 and 82 years old (median: 70 years). In all patients, cisplatinum (CDDP) (2 mg/kg), aclacinomycin (ACR) (0.5 mg/kg) and Angiotensin II (25 mg) were infused via the internal iliac artery for a period of about 30 minutes. Seven patients also received X-ray therapy with a linac. The efficacy of this therapy was assessed by computed tomographic scanning, sonography and cystoscopy. As a result of this assessment, 2 patients were rated complete response "(CR)", 6 partial response (PR) (showing 50% or more reduction in the lesion) and 2 no change "(NC)". To compare the efficacy of this therapy for two histopathologically defined groups of patients (patients with grades 2 and 3 cancer), one patient was rated "CR", four "PR" and two "NC" in the grade 3 group (total 7 patients), while one was rated "CR" and two "PR", in the grade 2 group (total 3 patients). In effective cases, pollakiuria and miction pain disappeared shortly following intra-arterial infusion therapy. As for side effects of the therapy, mild nausea or vomiting was observed in all patients, while leukopenia was noted in one patient.
 ...
PMID:[Treatment of advanced bladder cancer with intra-arterial infusion of cisplatinum (CDDP) and aclacinomycin (ACR), combined with angiotensin II]. 342 16

We evaluated the effects of 4'-epi-Adriamycin (EPI), a derivative of Adriamycin (ADR), in intravesical instillation chemotherapy. The patients received two courses of three daily instillations of 50-80 mg EPI dissolved in 30 ml physiological saline on 3 consecutive days, with an interval of 4 days between courses. Full evaluation was possible in 33 of 35 patients with superficial bladder tumors treated with EPI. Complete response was observed in 4 cases and partial response in 14 cases, giving a response rate of 55%. Side effects such as pollakiuria and pain on micturition occurred in 9 cases. EPI appears to be an effective agent for intravesical instillation chemotherapy in patients with superficial bladder tumors.
Cancer Chemother Pharmacol 1986
PMID:Intravesical chemotherapy with 4'-epi-Adriamycin in patients with superficial bladder tumors. 345 82

Investigation of micturition and drinking habits in urban (n = 475) and rural (n = 156) working populations demonstrated less frequent micturition, decreased fluid intake, and a higher urine concentration in the urban as compared to the rural group. All these differences were significant (P less than .01) by multivariate analysis, adjusting for age and sex differences. Drinking and micturition habits were similar in both sexes, but urine concentration was significantly lower in females (P less than .01) in both the urban and rural groups. Incidence of bladder cancer is reportedly higher in urban versus rural populations and in males versus females, the differences being apparently unaccountable for by differences in smoking, an important risk factor for bladder cancer. Our findings of greater urine concentration and less frequent micturition (which augments urine contact with bladder epithelium) in high-risk groups for bladder cancer are consistent with the "urogenous contact hypothesis." This hypothesis associates the etiology of bladder cancer with prolonged exposure to urine, on the basis of studies indicating carcinogenicity of urine. Further studies should indicate whether frequent drinking and urination are effective preventive measures against bladder cancer.
J Natl Cancer Inst 1987 Mar
PMID:Drinking, micturition habits, and urine concentration as potential risk factors in urinary bladder cancer. 346 57

In an experimental study undertaken to elucidate the mechanism whereby Adriamycin (ADM) instilled into the bladder produces its side-effects, the time course of ADM concentration in blood, urine, and tissues of various organs, and also histopathological changes in the bladder mucosa were investigated in normal adult dogs that had undergone bilateral ureterostomy and then received intravesically instilled ADM. Clinically, ADM was used in the treatment of superficial bladder tumors in an attempt to facilitate the transurethral operative procedure. A total of 261 patients were included in this trial. ADM was instilled into the bladder at the following dosages: 1,000 micrograms/ml (30 mg ADM per 30 ml physiological saline), 1,600 micrograms/ml (50 mg ADM per 30 ml physiological saline), and 2,000 micrograms/ml (60 mg ADM per 30 ml physiological saline). The rate of effectiveness was 32%, 66%, and 60%, respectively. The incidence of side-effects was 29%, 20%, and 45%, respectively. The systemic uptake of the drug was small and the side-effects were pain an micturition, pollakiuria, and urgency. From the aspects of efficacy and toxicity, 1,600 micrograms/ml was found to be the optimal dosage.
Cancer Chemother Pharmacol 1983
PMID:Intravesical adriamycin chemotherapy in bladder cancer. 664 Aug 38


1 2 3 4 5 6 Next >>